CERo Capital Lease Obligations vs Accounts Payable Analysis
| CEROW Stock | 0.01 0.00 0.000004% |
CERo Therapeutics financial indicator trend analysis is way more than just evaluating CERo Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether CERo Therapeutics is a good investment. Please check the relationship between CERo Therapeutics Capital Lease Obligations and its Accounts Payable accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CERo Therapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
Capital Lease Obligations vs Accounts Payable
Capital Lease Obligations vs Accounts Payable Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of CERo Therapeutics Capital Lease Obligations account and Accounts Payable. At this time, the significance of the direction appears to have pay attention.
The correlation between CERo Therapeutics' Capital Lease Obligations and Accounts Payable is -0.93. Overlapping area represents the amount of variation of Capital Lease Obligations that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of CERo Therapeutics Holdings, assuming nothing else is changed. The correlation between historical values of CERo Therapeutics' Capital Lease Obligations and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Lease Obligations of CERo Therapeutics Holdings are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Capital Lease Obligations i.e., CERo Therapeutics' Capital Lease Obligations and Accounts Payable go up and down completely randomly.
Correlation Coefficient | -0.93 |
| Relationship Direction | Negative |
| Relationship Strength | Significant |
Capital Lease Obligations
CERo Therapeutics capital lease obligations are the amount due for long-term lease agreements that are nearly equivalent to CERo Therapeutics asset purchases. For example, CERo Therapeutics can use a capital lease to finance the purchase of an asset without ever buying it. A capital lease gives companies such as CERo Therapeutics control over an asset for a big portion of its life. The total obligations of a company under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee.Accounts Payable
An accounting item on the balance sheet that represents CERo Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of CERo Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Most indicators from CERo Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into CERo Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CERo Therapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. Selling General Administrative is likely to drop to 2,748 in 2024. Enterprise Value Over EBITDA is likely to drop to -31.51 in 2024
| 2010 | 2022 | 2023 | 2024 (projected) | Interest Income | 986.7K | 142.1K | 127.9K | 121.5K | Net Interest Income | 986.7K | 142.1K | 127.9K | 121.5K |
CERo Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
CERo Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for CERo Stock Analysis
When running CERo Therapeutics' price analysis, check to measure CERo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CERo Therapeutics is operating at the current time. Most of CERo Therapeutics' value examination focuses on studying past and present price action to predict the probability of CERo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CERo Therapeutics' price. Additionally, you may evaluate how the addition of CERo Therapeutics to your portfolios can decrease your overall portfolio volatility.